Status:

RECRUITING

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis

Lead Sponsor:

Universitaire Ziekenhuizen KU Leuven

Collaborating Sponsors:

Fonds voor Wetenschappelijk Reumaonderzoek (FWRO)

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The goal of this open label multicenter randomized controlled pragmatic superiority trial is to investigate the optimal treatment/tapering strategy with rituximab for patients with rheumatoid arthriti...

Eligibility Criteria

Inclusion

  • Able and willing to give written informed consent and participate in the study before any study procedure.
  • Age ≥ 18 years.
  • Understanding and able to write in Dutch or French.
  • Diagnosis of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for rheumatoid arthritis.
  • Previous response to rituximab, defined as a minimum of one successful rituximab cycle (= a moderate/good EULAR response 16 weeks after the first administration of rituximab).
  • Current treatment with rituximab.
  • Need for a subsequent rituximab cycle according to the Belgian reimbursement criteria for the use of rituximab in rheumatoid arthritis (DAS28 score ≥3.2).
  • Stable dose of methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (DMARDs) 4 weeks prior to baseline.

Exclusion

  • Current treatment with another biological DMARD than rituximab.
  • Current treatment with a targeted synthetic DMARD.
  • Pregnancy or pregnancy wish.
  • Presence of an absolute contraindication to treatment with rituximab, according to the label of rituximab and according to medical judgement.

Key Trial Info

Start Date :

January 9 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

134 Patients enrolled

Trial Details

Trial ID

NCT06003283

Start Date

January 9 2024

End Date

December 1 2027

Last Update

May 31 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

ZNA Jan Palfijn

Merksem, Antwerpen, Belgium, 2170

2

Cliniques Universitaires Saint-Luc Bruxelles

Brussels, Brussels Capital, Belgium, 1000

3

Reumacentrum Genk

Genk, Limburg, Belgium, 3600

4

ReumaClinic Genk

Genk, Limburg, Belgium, 3600

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis | DecenTrialz